Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001

NEXT STORY
OSE Immunotherapeutics Announces First Peer-Reviewed Publication in “Science Advances” on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation
PREV STORY
Care With Love: Virginia Based In-Home Care Provider Achieves Rapid Growth
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

XBiotech Announces Addition of Dr. Dirk Arnold to its Scientific Advisory Board

AUSTIN, Texas, March 23, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that ...

author_avatar
NASDAQ Market News

Delcath Announces Accelerated Listing on OTCQB

NEW YORK, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional ...

author_avatar
NASDAQ Market News

Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China

PLYMOUTH MEETING, Pa., March 20, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today ...

author_avatar
NASDAQ Market News